Circumscribed focal atrophy with frontal lobe dementia and progressive aphasia, as described originally by Arnold Pick, has been recognized recently as being much more common than previously believed. Although Pick disease became linked with argyrophilic inclusions (Pick bodies) and swollen neurons (Pick cells), the majority of focal atrophies have findings that are a variation of the classic histologic features. We discuss Pick's background and the circumstances that led to his major contributions to the study of behavioral neurology. We also review his original articles, the articles that subsequently established the entity of Pick disease, and historical documents pertaining to the continuation of German-language education in Prague after Prague's independence from the Austro-Hungarian monarchy. Arnold Pick's life and career exemplify the integration of neurology, psychiatry, and neuropathology, which represents one of the major contributions of German neuropsychiatry to the study of the nervous system. Pick is a major intellectual ancestor of present-day neurology.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/archneur.1996.00550090147021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Neurological eponyms? Take your Pick.
Pract Neurol
November 2024
Dementia Research Centre, UCL Queen Square Institute of Neurology, University College London, London, UK
The neuropsychiatrist Arnold Pick (1851-1924) lent his name to a disease, but in his centenary year, it is timely to ask whether this and the many other eponyms that populate neurology are more help than hindrance. Here, I survey some neurological eponyms, propose criteria for judging their helpfulness (and unhelpfulness) and consider their future prospects in our increasingly mechanistic, contemporary neurological practice.
View Article and Find Full Text PDFBackground: Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-TS), also known as multisystem inflammatory syndrome in children (MIS-C) emerged in April, 2020. The paediatric comparisons within the RECOVERY trial aimed to assess the effect of intravenous immunoglobulin or corticosteroids compared with usual care on duration of hospital stay for children with PIMS-TS and to compare tocilizumab (anti-IL-6 receptor monoclonal antibody) or anakinra (anti-IL-1 receptor antagonist) with usual care for those with inflammation refractory to initial treatment.
Methods: We did this randomised, controlled, open-label, platform trial in 51 hospitals in the UK.
Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Lancet Diabetes Endocrinol
December 2023
Background: Empagliflozin has been proposed as a treatment for COVID-19 on the basis of its anti-inflammatory, metabolic, and haemodynamic effects. The RECOVERY trial aimed to assess its safety and efficacy in patients admitted to hospital with COVID-19.
Methods: In the randomised, controlled, open-label RECOVERY trial, several possible treatments are compared with usual care in patients hospitalised with COVID-19.
Article Synopsis
- A study evaluated the effects of a higher dose of corticosteroids on COVID-19 patients who needed oxygen or ventilatory support, building on previous findings that low-dose corticosteroids reduced mortality in similar patients.
- The research was part of the RECOVERY trial, which randomly assigned patients to receive either higher dose corticosteroids or usual care with a lower dose, measuring 28-day mortality rates as the primary outcome.
- From May 2021 to May 2022, 1,272 patients were included, with notable participation from Asia and the UK; results showed that nearly all of the patients who received usual care also received some form of low-dose corticosteroids.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!